- Intravenous stem cell infusion produced from umbilical cords seems to improve heart muscle function in patients with heart failure, based on a little study.
- Within this first-of-its-kind study, patients had “significant” improvement within their hearts’ capability to pump bloodstream and experienced no adverse negative effects associated with the treatment.
- The outcomes suggest IV-infused umbilical cord-derived stem cells really are a promising avenue to deal with heart failure.
Embargoed until 3 p.m. CT / 4 p.m. ET Tuesday, September 26, 2017
DALLAS, Sept. 26, 2017 – A heart failure treatment using umbilical cord-derived stem cells can lead to notable enhancements in heart muscle function and excellence of existence, according to a different study printed in Circulation Research, a united states Heart Association journal.
“We are encouraged by our findings simply because they could pave the best way to a non-invasive, promising new therapy for several patients who face harsh odds,” stated study corresponding author Fernando Figueroa, M.D., professor of drugs in the Universidad de los Andes in Chile.
Within this trial, 30 volunteers, ages 18 to 75, with stable heart failure receiving optimal drug therapy went through intravenous infusions with either umbilical cord-derived stem cells or placebo. The umbilical cords were acquired from full-term human placentas from healthy contributors by caesarean section after informed consent.
When compared to placebo treatment, the stem cell therapy:
- demonstrated sustained and “significant” improvement within the hearts’ capability to pump bloodstream around following treatment
- led to greater enhancements on measures of daily functional status and excellence of existence and
- was safe without any negative effects or growth and development of alloantibodies, a typical immune complication in patients receiving organ transplants or bloodstream transfusions.
Scientific study has formerly assessed the potential for bone marrow-derived stem cells as treatment however, intravenous umbilical cord-derived stem cells haven’t been evaluated. The second type continues to be particularly appealing since they’re readily available, broadly available, unlikely to result in immune complications and free from the moral concerns that surround embryonic stem cells, they noted.
“Standard drug-based regimens could be suboptimal in managing heart failure, and patients frequently need to progress to more invasive therapies for example mechanical ventricular assist devices and heart transplantation,” stated lead study author Jorge Bartolucci M.D., a cardiologist from Cells for Cells and professor in the Universidad de los Andes.
Heart failure, marked through the heart muscle’s lack of ability to function bloodstream efficiently, affects some 37 million people worldwide. Despite medical advances, 1 / 2 of patients identified as having heart failure will die within 5 years of diagnosis, based on Figueroa. If affirmed in bigger studies, these bits of information could give a promising new treatment choice for a disorder that presently has couple of.
Other co-authors incorporated Fernando J. Verdugo, M.D. Paz L. González, B.Sc. Ricardo E. Larrea, M.D. Ema Abarzua, M.D. Carlos Goset, M.D. Pamela Rojo, M.D. Ivan Palma, M.D. Ruben Lamich, M.D. Pablo A. Pedreros, M.D. Gloria Valdivia, Ph.D. Valentina M. Lopez, B.Sc. Carolina Nazzal, Ph.D. Francisca Alcayaga, Ph.D. Jimena Cuenca, Ph.D. Matthew J. Brobeck, B.Sc. Amit N. Patel, M.D. and Maroun Khoury, Ph.D. Author disclosures take presctiption the manuscript.
The research was funded with a grant from CORFO, the Chilean Economic Development Agency.
Statements and conclusions of study authors printed in American Heart Association scientific journals are exclusively individuals from the study authors and don’t always reflect the association’s policy or position. The association will not make any representation or guarantee regarding their precision or reliability. The association receives funding mainly from individuals foundations and corporations (including pharmaceutical, device manufacturers along with other companies) also make donations and fund specific association programs and occasions. The association has strict policies to avoid these relationships from influencing the science content. Revenues from pharmaceutical and device corporations and medical health insurance providers can be found at world wide web.heart.org/corporatefunding.
Concerning the American Heart Association
The American Heart Association is dedicated to saving individuals from cardiovascular disease and stroke – the two leading reasons for dying on the planet. We team with countless volunteers to finance innovative research, fight for more powerful public health policies and supply lifesaving tools and knowledge to avoid and treat these illnesses. The Dallas-based association may be the nation’s earliest and largest voluntary organization focused on fighting cardiovascular disease and stroke. To find out more in order to become involved, call 1-800-AHA-USA1, visit heart.org or call any one of our offices round the country. Follow us on Twitter and facebook.
For Media Queries and AHA/ASA Spokesperson Perspective: 214-706-1173
Bridgette McNeill: 214-706-1135 [email protected]
For Public Queries: 1-800-AHA-USA1 (242-8721)
heart.org and strokeassociation.org